CD274 and neoplasm: (2) Genetic biomarkers include oncogenic mutations, the tumor mutational burden (TMB), and DNA mismatch repair (MMR) deficiency in cancer cells, which may correlate with the response and resistance to PD1/PDL1 therapy.